This morning, the district court in Janssen v. Samsung Bioepis, which concerns Samsung Bioepis’ Renflexis® (infliximab-abda) biosimilar product, entered a pretrial scheduling order. The scheduling order calls for, among other things, fact discovery to close on August 30, 2018, expert discovery to close on January 31, 2019, and any dispositive motions to be filed by March 1, 2019. The scheduling order does not set a date for trial, the final pretrial conference or submitting the final pretrial order. However, based on the schedule, the case may be trial-ready by mid-2019.
Stay tuned for further updates about this case.
